As one of the core companies in the Fujifilm Group's healthcare segment, we are committed to solving social issues through the pharmaceutical business.
In the field of anti-infective drugs, including antibacterials and antivirals, which are our main small molecule pharmaceutical business, concerns are emerging about drug-resistant bacteria (the so-called silent pandemic) and national policies to ensure domestic stable supply. As one of the few companies that can manufacture anti-infective drugs by complying with strict manufacturing controls, we will continue to support people's health and take action to solve social issues.
In the biopharmaceutical field, there has been a demand in recent years for manufacturing facilities in Japan to support various new modalities and DDS (drug delivery system) technologies as new drugs are developed to address unmet medical needs. In cooperation with FUJIFILM Diosynth Biotechnologies known as one of the global bio-CDMOs, we will contribute to Japan’s biotechnology industry as a bio-CDMO on global standard.
We are committed to addressing social issues by leveraging the collective efforts of our dedicated employees in pursuit of our Fujifilm Group Purpose: Giving our world more smiles. We sincerely appreciate and look forward to your continued support.
Mitsuhiro Sato
President and Representative Director